Mineralys Therapeutics (MLYS) Following Russell Index Removal Still Looks Cheap On Fair Value
Mineralys Therapeutics (MLYS) has been removed from several Russell indices, including the Russell Microcap and Russell 3000E families. This change can prompt mechanical trading as passive index funds rebalance.
See our latest analysis for Mineralys Therapeutics.
Mineralys Therapeutics has seen short term price volatility around the index removals, with a 1 day share price return of down 4.74%. However, the 30 day share price return of 19.77% and 90 day share price return of 8.79% sit alongside a 1 year total shareholder return of 97.81% and 3 year total shareholder return of 86.36%, suggesting earlier momentum has cooled somewhat year to date.
If you are weighing Mineralys Therapeutics against other healthcare opportunities, it can help to see what else is moving in AI powered medicine by checking the 40 healthcare AI stocks.
Mineralys Therapeutics now trades at a steep discount to both analyst targets and an implied intrinsic value. Yet the stock has already pulled back year to date, so is the market’s caution sensible or overly harsh?
Most Popular Narrative: 43.1% Undervalued
On Simply Wall St’s most followed narrative, Mineralys Therapeutics screens as materially undervalued, with a fair value of $50.88 against a last close of $28.96, setting up a wide gap between narrative and market pricing.
Clinical focus on high risk, hard to treat hypertension in a large U.S. population of over 20 million patients aligns the lorundrostat program with an established, chronic therapy market, which can be supportive for longer duration prescription use and recurring revenue if uptake is achieved.
Want to see what sits behind that gap between price and fair value? The most followed narrative leans on aggressive revenue build, margin lift and a demanding future earnings multiple. Interested in how those moving parts combine into a single number investors keep watching?
Result: Fair Value of $50.88 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Mineralys Therapeutics still faces meaningful risk if lorundrostat hits regulatory setbacks or if class competition limits pricing power and slows adoption.
Find out about the key risks to this Mineralys Therapeutics narrative.
Next Steps
With Mineralys Therapeutics pulling in both optimism and concern, do not wait on others to shape the story for you; weigh the 2 key rewards and 4 important warning signs.
Looking for more investment ideas beyond Mineralys Therapeutics?
If you are ready to broaden your watchlist beyond Mineralys Therapeutics, use targeted stock lists to quickly surface fresh ideas that fit how you like to invest.
- Zero in on value by scanning companies that currently appear mispriced relative to their fundamentals with the 44 high quality undervalued stocks.
- Steady your portfolio with businesses that pair stronger balance sheets with healthier fundamentals by checking the solid balance sheet and fundamentals stocks screener (47 results).
- Get ahead of the crowd by tracking a focused screener containing 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com